Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Healthcare Professionals / OncoLink Scientific Meetings Coverage / PTCOG / OncoLink at PTCOG 2009 / October 2, 2009
OncoLink reporters provide up-to-date coverage of the Particle Therapy Cooperative Group (PTCOG) 48 Conference in Heidelberg, Germany, September 28 - October 3, 2009.
|
Interfractional Variation in the Set-up of Pelvic Bony Anatomy and Soft Tissue, and Their Implications in Proton Therapy of the Prostate
Presenter: A. TrofimovPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground As proton therapy becomes more widely available, more and more patients with prostate cancers receive definitive... |
|
|
Late Effects of Particle Radiation
Presenter: E. BlakelyPresenter's Affiliation: Berkeley Laboratory, San Francisco, CaliforniaType of Session: ScientificBackground Dr. Blakely gave a comprehensive discussion of the published literature regarding late effects of radiation with protons... |
|
|
Multi-Institutional Phase II Study of Proton Beam Therapy for Organ Confined Prostate Cancer in Japan, Focusing on the Incidence of Late Rectal Toxicities
Presenter: Dr. K. NiheiPresenter's Affiliation: Shizuoka Cancer Center, Shizuoka, JapanType of Session: ScientificBackground At present, IMRT is the predominant modality used to treat prostate cancer using radiation Dose escalation has... |
|
|
Novel Techniques in Proton Treatment and Challenges with Heavy Ion Radiotherapy
Presenter: Dr. K. HerfarthPresenter's Affiliation: Heidelberg, GermanyType of Session: Scientific This presentation is a discussion of the current research projects that are ongoing at the Heidelberg heavy ion facility, as well as planned future... |
|
|
Proton Radiation Therapy for Patients with Prostate Cancer
Presenter: C. RossiPresenter's Affiliation: Loma Linda, USAType of Session: ScientificBackground The most effective treatment for clinically localized prostate cancer remains controversial, as no randomized trials comparing radiation therapy to... |
|
|
Proton treatment of prostate cancer in the presence of unilateral hip replacement
Presenter: M. Fitzek, K. Shahnazi, J. Simmons, A. ThorntonPresenter's Affiliation: Midwest Proton Radiotherapy Institute, Bloomington, IN, USAType of Session: ScientificBackground Options for the treatment of clinically localized prostate... |
Dr. O'Dwyer discusses pancreatic cancer, family history, screening and future research. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

